[go: up one dir, main page]

IN2014DE01467A - - Google Patents

Info

Publication number
IN2014DE01467A
IN2014DE01467A IN1467DE2014A IN2014DE01467A IN 2014DE01467 A IN2014DE01467 A IN 2014DE01467A IN 1467DE2014 A IN1467DE2014 A IN 1467DE2014A IN 2014DE01467 A IN2014DE01467 A IN 2014DE01467A
Authority
IN
India
Prior art keywords
hot
melt
temperature
drug
melt extrusion
Prior art date
Application number
Inventor
Shogo Warashina
Fumie Kusaki
Kazuki Kikuchi
Sakae Obara
Naosuke Maruyama
Original Assignee
Shinetsu Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50842156&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DE01467(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shinetsu Chemical Co filed Critical Shinetsu Chemical Co
Publication of IN2014DE01467A publication Critical patent/IN2014DE01467A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B11/00—Preparation of cellulose ethers
    • C08B11/193—Mixed ethers, i.e. ethers with two or more different etherifying groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B11/00—Preparation of cellulose ethers
    • C08B11/20—Post-etherification treatments of chemical or physical type, e.g. mixed etherification in two steps, including purification
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B13/00—Preparation of cellulose ether-esters
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/20—Compounding polymers with additives, e.g. colouring
    • C08J3/201—Pre-melted polymers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08—Cellulose derivatives
    • C08L1/32—Cellulose ether-esters
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2301/00—Characterised by the use of cellulose, modified cellulose or cellulose derivatives
    • C08J2301/08—Cellulose derivatives
    • C08J2301/32—Cellulose ether-esters

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided area composition for hot-melt extrusion which can be hot-melt extruded at a temperature lower than a conventional temperature and therefore free of heat-induced deactivation of a drug; and a method for producing a hot-melt extrusion product which is simpler than a spray-drying method. More specifically, provided is a composition for hot-melt extrusion comprising a drug and hypromellose acetate succinate (HPMCAS) having a hydroxypropoxy molar substitution of 0.40 or more. Also provided is a method for producing a hot-melt extrusion product comprising a step of hot-melt extruding a composition for hot-melt extrusion comprisinga drug and hypromellose acetate succinate having a hydroxypropoxy molar substitution of 0.40 or more at a hot-melt temperature of melting temperature of the hypromellose acetate succinate or higher, or at a hot-melt temperature equal to or higher than a temperature at which both the hypromellose acetate succinate and the drug become melted.
IN1467DE2014 2013-06-03 2014-06-03 IN2014DE01467A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013116836 2013-06-03
JP2013246178 2013-11-28

Publications (1)

Publication Number Publication Date
IN2014DE01467A true IN2014DE01467A (en) 2015-07-24

Family

ID=50842156

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1467DE2014 IN2014DE01467A (en) 2013-06-03 2014-06-03

Country Status (8)

Country Link
US (2) US10646573B2 (en)
EP (2) EP2810660B1 (en)
JP (2) JP6007322B2 (en)
KR (2) KR101918327B1 (en)
CN (2) CN105283203B (en)
IN (1) IN2014DE01467A (en)
PT (2) PT2810660T (en)
WO (1) WO2014196519A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2810660B1 (en) 2013-06-03 2017-07-26 Shin-Etsu Chemical Co., Ltd. Composition for hot-melt extrusion and method for producing hot-melt extrusion product using same
JP6203702B2 (en) 2014-11-18 2017-09-27 信越化学工業株式会社 Solution for spray drying using hypromellose acetate succinate and method for producing solid dispersion
JP6657223B2 (en) 2014-12-18 2020-03-04 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． (S) -N- (3- (6-Isopropoxypyridin-3-yl) -1H-indazol-5-yl) -1- (2- (4- (4- (1-methyl) for pharmaceutical preparations -1H-1,2,4-triazol-3-yl) phenyl) -3,6-dihydropyridin-1 (2H) -yl) -2-oxoethyl) -3- (methylthio) pyrrolidine-3-carboxamide composition
CN107567463A (en) * 2015-05-15 2018-01-09 陶氏环球技术有限责任公司 The technique for preparing HMW esterified cellulose ether
KR20180008524A (en) * 2015-05-15 2018-01-24 다우 글로벌 테크놀로지스 엘엘씨 Process for preparing ultrahigh molecular weight and low viscosity esterified cellulose ether
JP6426877B2 (en) * 2015-07-28 2018-11-21 ダウ グローバル テクノロジーズ エルエルシー Process for producing a dispersion of esterified cellulose ether
EP3596132B1 (en) 2017-03-17 2021-05-05 Nutrition & Biosciences USA 1, LLC Process for recovering an esterified cellulose ether from a reaction product mixture
WO2018170060A1 (en) 2017-03-17 2018-09-20 Dow Global Technologies Llc Process for recovering an esterified cellulose ether from a reaction product mixture
WO2018170083A1 (en) 2017-03-17 2018-09-20 Dow Global Technologies Llc Process for recovering an esterified cellulose ether from a reaction product mixture
US20180282527A1 (en) * 2017-03-30 2018-10-04 Shin-Etsu Chemical Co., Ltd. Injection molding composition containing hypromellose acetate succinate and method for producing same
CN109078186B (en) * 2017-06-14 2021-09-03 江苏恒瑞医药股份有限公司 Gastric floating composition and preparation method thereof
TR201722852A2 (en) * 2017-12-29 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Oral pharmaceutical compositions of mesalazine
WO2020131801A1 (en) 2018-12-18 2020-06-25 DDP Specialty Electronic Materials US, Inc. A sustained release composition comprising a hydroxypropyl methylcellulose acetate succinate
JP7050714B2 (en) * 2019-04-04 2022-04-08 信越化学工業株式会社 Method for Producing Composition for Enteric Coating and Solid Formula
JP7273691B2 (en) 2019-11-01 2023-05-15 信越化学工業株式会社 Method for producing hydroxypropyl methylcellulose phthalate
JP7252882B2 (en) * 2019-11-01 2023-04-05 信越化学工業株式会社 Method for producing hydroxypropyl methylcellulose acetate succinate
WO2021118915A1 (en) 2019-12-09 2021-06-17 Nutrition & Biosciences Usa 1, Llc Hydroxypropyl alkyl cellulose acetate succinate heteropolymers
EP4196096A1 (en) 2020-08-13 2023-06-21 Alfred E. Tiefenbacher (GmbH & Co. KG) Gastro-resistant high-strength formulation containing posaconazole
JP7399060B2 (en) * 2020-10-01 2023-12-15 信越化学工業株式会社 Method for producing hydroxypropyl methylcellulose acetate succinate
EP4091604B1 (en) 2021-11-25 2024-04-03 Alfred E. Tiefenbacher (GmbH & Co. KG) Granules containing posaconazole
CN115581678B (en) * 2022-11-04 2023-09-12 北京鑫开元医药科技有限公司 A kind of repetinib tablet composition and preparation method thereof
CN115651085B (en) * 2022-11-14 2023-11-17 乳源东阳光药业有限公司 Purification method of hydroxypropyl methylcellulose acetate succinate

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3852421A (en) 1970-03-23 1974-12-03 Shinetsu Chemical Co Excipient and shaped medicaments prepared therewith
US4226981A (en) * 1977-09-28 1980-10-07 Shin-Etsu Chemical Co., Ltd. Ether-ester derivatives of cellulose and their applications
JPS5951562B2 (en) 1977-10-25 1984-12-14 信越化学工業株式会社 Method for producing acidic succinyl and aliphatic monoacyl mixed ester of cellulose ether
US4266981A (en) 1978-03-08 1981-05-12 Purdue Research Corporation Process for recovering and utilizing cellulose using sulfuric acid
DE19504832A1 (en) * 1995-02-14 1996-08-22 Basf Ag Solid drug preparations
AR038375A1 (en) 2002-02-01 2005-01-12 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS OF INHIBITORS OF THE PROTEIN OF TRANSFER OF ESTERES DE COLESTERILO
JPWO2003077827A1 (en) 2002-03-19 2005-07-14 日本新薬株式会社 Method for producing pharmaceutical solid dispersion
KR100454394B1 (en) 2002-03-27 2004-10-26 이원희 A mechanocardiogram detector
JP4344914B2 (en) * 2003-02-28 2009-10-14 信越化学工業株式会社 Alkali-soluble carboxylic acid ester-based cellulose derivative and film comprising the derivative
US8207232B2 (en) * 2004-05-28 2012-06-26 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
US20080213383A1 (en) * 2005-09-06 2008-09-04 Astellas Pharma Inc. Fine particles of poorly water-soluble drug having enteric material adsorbed on particle surface
JP5576922B2 (en) * 2006-04-20 2014-08-20 信越化学工業株式会社 Solid formulation comprising an enteric solid dispersion
JP5070618B2 (en) * 2006-06-16 2012-11-14 トーアエイヨー株式会社 Enteric granules and method for producing the same
JP5052051B2 (en) * 2006-06-16 2012-10-17 トーアエイヨー株式会社 Enteric granules and method for producing the same
MX2009004143A (en) * 2006-10-20 2009-11-26 Dow Global Technologies Inc Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome.
EP2278957A2 (en) 2008-04-15 2011-02-02 Schering Corporation Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
NZ588460A (en) * 2008-04-15 2012-07-27 Schering Corp Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
EP2927720B1 (en) 2010-02-03 2018-10-17 Tyco Electronics Nederland B.V. Enclosure assembly for a connector, strain relief element, and method
KR101807338B1 (en) * 2010-06-14 2018-01-10 다우 글로벌 테크놀로지스 엘엘씨 Hydroxypropyl methyl cellulose acetate succinate with enhanced acetate and succinate substitution
US8409560B2 (en) * 2011-03-08 2013-04-02 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
AU2012225459A1 (en) 2011-03-08 2013-10-10 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
US20120251588A1 (en) * 2011-03-30 2012-10-04 Miyuki Fukasawa Coating Composition, Solid Preparation Coated Therewith, and Method for Preparing Solid Preparation
JP2013116836A (en) 2011-12-02 2013-06-13 Sharp Corp Method for reutilizing silicon offcut, raw material silicon, polysilicon material, and method for manufacturing polysilicon solar cell
DE102012010430A1 (en) 2012-05-29 2013-12-05 Krohne Ag Flowmeter
WO2014031422A1 (en) 2012-08-24 2014-02-27 Dow Global Technologies Llc Novel hydroxyalkyl methyl cellulose acetate succinates
EP2810660B1 (en) 2013-06-03 2017-07-26 Shin-Etsu Chemical Co., Ltd. Composition for hot-melt extrusion and method for producing hot-melt extrusion product using same

Also Published As

Publication number Publication date
US20160095928A1 (en) 2016-04-07
CN104208713A (en) 2014-12-17
KR101918327B1 (en) 2018-11-13
JP6126555B2 (en) 2017-05-10
KR20140142173A (en) 2014-12-11
EP3006049B1 (en) 2018-02-28
EP3006049A4 (en) 2017-02-22
EP3006049A1 (en) 2016-04-13
KR102228157B1 (en) 2021-03-17
WO2014196519A1 (en) 2014-12-11
CN105283203A (en) 2016-01-27
US10016508B2 (en) 2018-07-10
EP2810660B1 (en) 2017-07-26
CN104208713B (en) 2018-04-27
JP6007322B2 (en) 2016-10-12
PT3006049T (en) 2018-03-20
EP2810660A1 (en) 2014-12-10
JP2015127316A (en) 2015-07-09
US10646573B2 (en) 2020-05-12
JPWO2014196519A1 (en) 2017-02-23
KR20160015234A (en) 2016-02-12
US20140357681A1 (en) 2014-12-04
PT2810660T (en) 2017-08-16
CN105283203B (en) 2018-12-28

Similar Documents

Publication Publication Date Title
IN2014DE01467A (en)
HUE066810T2 (en) Stabilized fluoroolefin compositions and process for their production, storage and use
AU2019268159A1 (en) Systems and methods for synthesizing chemical products, including active pharmaceutical ingredients
EP4449901A3 (en) Capsule for tobacco industry product
IN2014DE02197A (en)
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2014012527A (en) Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same.
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
EP3283470A4 (en) Processes for producing 2,5-furandicarboxylic acid and derivatives thereof and polymers made therefrom
EP2898948A4 (en) GLYCERIN DEHYDRATION CATALYST, PROCESS FOR PREPARING THE SAME, AND PROCESS FOR PRODUCING ACROLEIN
EP3315499A4 (en) CRYSTAL OF (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]- 4,7-DIOXO-8-({6-[3-(PIPERAZIN-1-YL)AZETIDIN-1-YL]PYRIDIN- 2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND
WO2015017478A3 (en) SYNTHESIS OF CdSe/ZnS CORE/SHELL SEMICONDUCTOR NANOWIRES
WO2015019198A3 (en) High potency pancreatin pharmaceutical compositions
ZA201600415B (en) Novel derivatives of indole and pyrrole, method for the production thereof and pharmaceutical compositions containing same
IN2013CH02295A (en)
PH12021550413A1 (en) Vitamin d pediatric dosage forms, methods of making and using
IN2014DE03239A (en)
TWI799564B (en) Process for the production of normal butanol, iso-butanol and 2-alkyl alkanol
SA517390475B1 (en) System of Multiple Bags and Method for The Preparation of Hemocomponents
SA520411635B1 (en) Fused Ring Derivative as A2A Receptor Inhibitor
SG11202105995QA (en) Co-crystal of ketoprofen, compositions comprising the same, process of producing the same, and uses thereof
WO2019240699A3 (en) Tablet formulations comprising metformin and sitagliptin processed with hot-melt extrusion
SMP201500110B (en) Stuffed food product, as well as the production method of this food product
MX2021003908A (en) Long-acting polypeptides and methods of producing and administering same.
WO2016161988A3 (en) Pharmaceutical composition containing spherical clopidogrel bisulphate crystalline form i, and preparation method for pharmaceutical composition